Webinar Date/Time: Tue, Jun 11, 2024 10:00 AM EDT
This webinar will cover the advantages of a fully automated in-line lysis system with a closed single-use loop for process development. In addition to state-of-the-art mixing control, it can be configured to automatically and continuously process up to 10–50 kg of resuspended E. coli cells every 8 hours.
Register Free: https://www.biopharminternational.com/bp_w/alkaline-lysis
Event Overview:
Generally, methods applied for the isolation of plasmid DNA involve a cell lysis step with the addition of a strong base (alkaline lysis), neutralization, and precipitation to recover the target pDNA in solution from precipitated contaminating cell components (genomic DNA, proteins, and protein-nucleic acid complexes). Uncontrolled use of an alkaline solution will degrade target pDNA, which is also sensitive to mechanical stress. Furthermore, highly viscous solutions may cause local heterogeneities or require extensive mixing, both potentially degrading the target pDNA. This webinar will present a fully automated in-line lysis system with a closed single-use loop for process development up to a pilot scale in the GMP environment. With a state-of-the-art mixing control, it can be configured to automatically and continuously process up to 10–50 kg of resuspended cells per workday depending on the configuration.
Key Learning Objectives:
Who Should Attend:
Speaker:
Matevz Korenc
Product Manager
Sartorius BIA Separations
After receiving a PhD in Biochemistry, Matevz Korenc continued as a team leader in Knauf insulation, where he managed the analytical support and material development in the EMEA region. Matevz joined Sartorius BIA Separations in 2021 as a project manager and two years later became fully active in in-line lysis machine development and GMP implementation. He is also an acrobatic basketball performer, never found in his comfort zone.
Register Free: https://www.biopharminternational.com/bp_w/alkaline-lysis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.